ABT-199 (venetoclax), a second-generation orally available derivative of ABT-737 that selectively targets BCL2 is currently under evaluation in clinical trials of B-cell NHL [367, 374, 375]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.